クリニカルリサーチセンター

Medicine & Life Sciences

1. Locus Coeruleus 100%
2. Chronic Obstructive Pulmonary Disease 88%
3. Japan 85%
4. Progeria short stature pigmented nevi 75%
5. Major Depressive Disorder 74%
6. Depression 61%
7. Alveolar Macrophages 60%
8. Vascular Endothelial Growth Factor A 57%
9. Smokers 56%
10. Nitrazepam 52%
11. zopiclone 51%
12. Calciphylaxis 51%
13. Lung 50%
14. Triazolam 49%
15. Psychiatry 49%
16. Protein Carbonylation 48%
17. Lipopolysaccharides 47%
18. NF-E2-Related Factor 2 47%
19. Warfarin 46%
20. Lung Injury 46%
21. Small Cell Lung Carcinoma 46%
22. Brain Stem 44%
23. Cytochrome P-450 CYP2C19 43%
24. Pulmonary Emphysema 43%
25. Smoke 43%
26. Tobacco Products 42%
27. CC Chemokines 42%
28. Pemphigus 41%
29. Cytochrome P-450 CYP2D6 41%
30. Renal Dialysis 41%
31. candesartan 40%
32. Imipramine 40%
33. Phenotype 40%
34. Risperidone 40%
35. Hepatocyte Growth Factor 39%
36. Pancreatic Elastase 39%
37. Bronchoalveolar Lavage Fluid 38%
38. Curcumin 37%
39. Pneumonia 37%
40. Alveolar Epithelial Cells 37%
41. Alleles 37%
42. Macrophages 37%
43. Microdialysis 37%
44. Cholinergic Antagonists 36%
45. Airway Obstruction 35%
46. Lung Neoplasms 35%
47. Transforming Growth Factors 34%
48. Granulocyte-Macrophage Colony-Stimulating Factor 34%
49. Acidosis 34%
50. Duodenum 33%
51. Emphysema 33%
52. Percutaneous Coronary Intervention 33%
53. Interleukin-8 31%
54. ErbB Receptors 31%
55. Acute Kidney Injury 31%
56. Citalopram 31%
57. Human Influenza 30%
58. Antihypertensive Agents 30%
59. Therapeutics 29%
60. Chronic Kidney Failure 29%
61. Single Nucleotide Polymorphism 27%
62. Pharmacokinetics 27%
63. Schizophrenia 27%
64. Small Cell Carcinoma 26%
65. Case-Control Studies 26%
66. Respiratory Rate 26%
67. Cardiovascular Diseases 26%
68. Inflammation 26%
69. Manufacturing Industry 25%
70. Desipramine 25%
71. Hypnotics and Sedatives 25%
72. Meta-Analysis 24%
73. Systematic Reviews 24%
74. Hypertension 24%
75. Ligands 23%
76. Swine 23%
77. Spinal Cord 22%
78. Cohort Studies 22%
79. Psychology 22%
80. Tomography 22%
81. Cerebrospinal Fluid 21%
82. Forced Expiratory Volume 21%
83. Prospective Studies 21%
84. Sprague Dawley Rats 21%
85. Costs and Cost Analysis 20%
86. Neoplasm Metastasis 20%
87. Pharmaceutical Preparations 19%
88. Benzodiazepines 19%
89. Brain 19%
90. Safety 19%
91. Clopidogrel 19%
92. Innate Immunity 19%
93. Drug Industry 19%
94. Non-Smokers 18%
95. keratinocyte-derived chemokines 18%
96. Nifedipine 18%
97. Neoplasms 17%
98. Logistic Models 17%
99. Antidepressive Agents 17%
100. Vascular Endothelial Growth Factor Receptor-1 17%